×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Company: Idorsia Pharmaceuticals Ltd.
company
3,906 words
2026-03-27
section:companies
kind:company
state:published
evidence:strong
topic:switzerland
topic:biotech
topic:alzheimer
topic:parkinson
topic:sleep
topic:neuroscience
Contents
Idorsia Pharmaceuticals Ltd.
Related Hypotheses (9)
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Aquaporin-4 Polarization Rescue
Score: 0.51
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme
Score: 0.48
Reelin-Mediated Cytoskeletal Stabilization Protocol
Score: 0.45
LRP1-Dependent Tau Uptake Disruption
Score: 0.44
Extracellular Vesicle Biogenesis Modulation
Score: 0.34
Show 4 more
Related Analyses (5)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Related Experiments (30)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.46
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.46
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.46
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.46
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.46
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.46
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.46
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.46
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.46
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.46
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.46
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.46
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.46
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.46
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.46
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.46
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.46
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.46
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.46
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.46
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.46
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.46
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.46
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.46
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.46
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.46
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.46
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.46
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.46
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.46
Show 25 more